Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome
- PMID: 8698749
- PMCID: PMC12201282
- DOI: 10.1007/BF01187161
Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome
Abstract
Objective: The objective of this study was to analyze the incidence of immunohistochemically detectable p53 protein accumulation in epithelial ovarian carcinomas and to correlate these data with the clinical outcome so as to clarify further the role of p53 mutations in prognosis with these patients.
Methods: Tumor tissues from 179 patients with epithelial ovarian carcinoma were used for immuno-histochemical analysis with monoclonal antibody DO1 and BP 53-12-1 on formalin-fixed, paraffin-embedded tissue.
Results: A total of 78 cases (44%) showed positive nuclear p53 staining. The p53-positive cases were found in all histological types of epithelial ovarian tumors. p53 staining was found in tumors of all stages with a higher percentage of positive cases in stage IV ovarian carcinomas (not significant). Poorly differentiated carcinomas showed a significantly higher percentage of p53 protein expression than did highly differentiated tumors (P = 0.0002). Clinical follow-up of up to 14 years (median 25 months) showed a slightly but not significantly shortened disease-free and overall survival time for patients with p53-positive epithelial ovarian carcinomas.
Conclusions: We conclude from our data that p53 expression in ovarian carcinoma is associated with poor differentiation but not with the disease being in an advanced stage. There was a tendency for shortened disease-free and overall survival for patients with p53-positive tumors.
Similar articles
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2. Cochrane Database Syst Rev. 2016. PMID: 26930463 Free PMC article.
-
Optimal primary surgical treatment for advanced epithelial ovarian cancer.Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2. Cochrane Database Syst Rev. 2011. PMID: 21833960 Free PMC article.
-
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.Cochrane Database Syst Rev. 2012 Mar 14;3(3):CD004706. doi: 10.1002/14651858.CD004706.pub4. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706. doi: 10.1002/14651858.CD004706.pub5. PMID: 22419298 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
Clear cell carcinomas of the mullerian system: does the pathogenesis vary depending on their nuclear grade and their association with endometriosis? An immunohistochemical analysis.Patholog Res Int. 2012;2012:674748. doi: 10.1155/2012/674748. Epub 2012 Nov 1. Patholog Res Int. 2012. PMID: 23213623 Free PMC article.
-
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.Br J Cancer. 1999 Oct;81(4):733-40. doi: 10.1038/sj.bjc.6690756. Br J Cancer. 1999. PMID: 10574264 Free PMC article.
-
Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.Br J Cancer. 2000 Feb;82(3):571-8. doi: 10.1054/bjoc.1999.0966. Br J Cancer. 2000. PMID: 10682668 Free PMC article.
-
p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity.J Cancer Res Clin Oncol. 1997;123(9):496-501. doi: 10.1007/BF01192204. J Cancer Res Clin Oncol. 1997. PMID: 9341899 Free PMC article.
-
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20. PLoS One. 2012. PMID: 23029043 Free PMC article.
References
-
- Banks L, Matlashewski G, Crawford L (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529–534 - PubMed
-
- Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699–1703 - PubMed
-
- Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC (1994) The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246–252 - PubMed
-
- Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6:1791–1797 - PubMed
-
- Day TG, Gallager HS, Rutledge FN (1975) Epithelial carcinoma of the ovary: Prognostic importance of histological grade. Natl Cancer Inst Monogr 42:15–18 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous